PLTR Draws Fresh Analyst Spotlight on AI Growth
Palantir is pulling renewed analyst attention in early July 2026 thanks to its rapid revenue expansion and AI platform momentum.
- Growth standout:...

Created by B Lai
Real‑time US stock news, earnings, and momentum ideas across large, small, and micro caps
Explore the latest content tracked by U.S. Stock Movers
Palantir is pulling renewed analyst attention in early July 2026 thanks to its rapid revenue expansion and AI platform momentum.
Money flowing from Big Tech into sectors like industrials, energy, banks, and consumer stocks is a bullish signal of a healthy market, creating...
OpenAI confidentially filed in June 2026 but is now weighing a 2027 delay after SpaceX's debut. Anthropic filed a week earlier and still eyes...
Small caps are outperforming large caps this year, with microcaps taking the top spot for YTD gains and the Russell 2000 posting its best first-half...
Intel and Micron both surged over 200% YTD on AI momentum, but their roles differ sharply.
Lumentum's 33% correction from its May 2026 peak unwinds valuation excess without breaking the core thesis. Structural AI demand in optical...
U.S. markets hit record highs in the first half, fueled by easing AI concerns and a U.S.-Iran pause.
The June 29 list features 50 high-momentum US stocks in strong uptrends relative to the S&P 500, far more than usual.
Two chip giants are surging on AI-driven demand for inference and manufacturing capacity.
Bitcoin's rebound is powering moves in crypto-exposed names as Robinhood debuts its new chain.
High-beta chip names faced sharp selling as investors rotated into defensive sectors like healthcare and staples.
Darling Ingredients options traders appear to be betting on a big move, with the July 17 $35 Call posting some of the highest implied volatility among equity options. The stock carries a Zacks Rank #1 Strong Buy rating.
StockStory flags two large caps with strong growth trajectories and one to avoid.
The FDA's expanded approval of Casgevy for children as young as 2 makes roughly 5,500 more U.S. patients eligible, driving CRSP shares up 8% and VRTX up 6%. CRISPR receives 40% of net profits from the one-time therapy.
US stock funds recorded $17.2 billion in net outflows for the week ending July 1, the largest weekly pull since March, with capital rotating into...
Addentax Group (NASDAQ:ATXG) has attracted heightened market interest after appearing among the US market's top daily gainers, with its low-float structure amplifying the sharp move in this China-based garment and logistics name.